EPO Antibody

中文名稱：

EPO兔多克隆抗體
貨號(hào)：

CSB-PA06339A0Rb
規(guī)格：

￥440
圖片：
Immunohistochemistry of paraffin-embedded human colon cancer using CSB-PA06339A0Rb at dilution of 1:100
其他：

產(chǎn)品詳情
產(chǎn)品評價(jià)
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

產(chǎn)品名稱：

Rabbit anti-Homo sapiens (Human) EPO Polyclonal antibody
Uniprot No.：

P01588
基因名：

EPO
別名：

EPOErythropoietin antibody; Epoetin antibody
宿主：

Rabbit
反應(yīng)種屬：

Human
免疫原：

Recombinant Human Erythropoietin protein (28-191AA)
免疫原種屬：

Homo sapiens (Human)

標(biāo)記方式：

Non-conjugated

本頁面中的產(chǎn)品，EPO Antibody (CSB-PA06339A0Rb)，的標(biāo)記方式是Non-conjugated。對于EPO Antibody，我們還提供其他標(biāo)記。見下表：

標(biāo)記方式	貨號(hào)	產(chǎn)品名稱	應(yīng)用
HRP	CSB-PA06339B0Rb	EPO Antibody, HRP conjugated	ELISA
FITC	CSB-PA06339C0Rb	EPO Antibody, FITC conjugated
Biotin	CSB-PA06339D0Rb	EPO Antibody, Biotin conjugated	ELISA

克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

ELISA, IHC

推薦稀釋比：

Application	Recommended Dilution
IHC	1:20-1:200

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
儲(chǔ)存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評價(jià)

靶點(diǎn)詳情

功能：

Hormone involved in the regulation of erythrocyte proliferation and differentiation and the maintenance of a physiological level of circulating erythrocyte mass. Binds to EPOR leading to EPOR dimerization and JAK2 activation thereby activating specific downstream effectors, including STAT1 and STAT3.
基因功能參考文獻(xiàn)：
1. Increases in plasma erythropoietin and erythropoietin receptor activation are mechanisms implicated in the increase of plasma FGF23 in acute kidney injury. PMID: 29395333
2. the implication of alpha-7-nAChR-JAK-2/STAT-3-Nrf-2 signaling cascade in the radiomitigative potential of EPO against ARS PMID: 29220591
3. Pro-inflammatory proteins S100A9 and tumor necrosis factor-alpha suppress erythropoietin elaboration in myelodysplastic syndromes PMID: 28983059
4. EPO levels in the coronary artery disease (CAD) group were higher than those in the non-CAD group. The correlation between red cell distribution width and EPO levels was statistically significant among CAD patients. PMID: 28885393
5. CD133(+) cells contributed to the local production of erythropoietin, as observed by detection of circulating human erythropoietin. CD133(+) cells appear therefore an effective source for cell repair, able to restore renal functions, including erythropoietin release, and to limit long term maldifferentiation and fibrosis. PMID: 27853265
6. Circulating anti-EPO are detected in a significant proportion of treatment-naive HCV-infected patients and are independently associated with anemia, suggesting a further implication of autoimmunity in the pathophysiology of HCV-related anemia. PMID: 28603097
7. the T allele of SNP rs60684937 located at 67,419,130 bp on chromosome 17 was associated with increased plasma EPO and a relatively increased expression of a non-coding transcript of PRKAR1A in sickle cell disease patients PMID: 28173069
8. study describes a gain-of-function variant in EPO in an extended kindred with familial erythrocytosis, including 10 affected family members in four generations; this mutation, a single-nucleotide deletion (c.32delG), introduces a frameshift in exon 2 PMID: 29514032
9. Here, using zebrafish, murine, and human models, the authors show that erythropoietin (EPO) signaling, together with the GATA1 transcriptional target, AKAP10, regulates heme biosynthesis during erythropoiesis at the outer mitochondrial membrane. PMID: 28553927
10. Reduction in central venous blood pressure prompts an increase in plasma EPO concentration independent of hemoconcentration and hence suggests CVP per se as an acute regulator of EPO synthesis PMID: 27169519
11. EPO (7q22) and SEC-61(7p11) emerged as new candidate genes susceptible to genetic losses with 57.7% deletions identified in regions on chromosome 7. PMID: 27282568
12. The current controversy may derive from a context-dependent mode of action of Epo, namely opposite skeletal actions during bone regeneration and steady-state bone remodeling. PMID: 26822707
13. High EPO expression is associated with monoclonal gammopathy of undetermined significance and multiple myeloma. PMID: 26919105
14. age 3 plasma levels of EPO were found related to childhood asthma PMID: 27434124
15. EPO induces an EMT-like process in mammary non-tumorigenic epithelial cells PMID: 28247960
16. these results suggested that quercetin's cytoprotective effects in HepG2 cells are mediated via EPO production. PMID: 29080630
17. Serum Epo and VEGF may be markers of severity of hypoxia-ischaemia and brain injury as they are closely related to hypoxic exposure. PMID: 27902983
18. CIS interacted with phosphorylated EpoR at Y401, which was critical for the activation of STAT5 and ERK. PMID: 28038963
19. EPO dependent regulation pathway of FGF23 gene expression PMID: 29073196
20. Fetal plasma EPO concentrations are selectively increased in monochorionic twin pregnancies with intrauterine growth restriction. PMID: 27161360
21. this study shows that EPO is involved in the pathogenesis of sepsis-induced acute kidney injury PMID: 27266727
22. Erythropoietin is superior to the standard prognostic scores in predicting 28-day mortality in patients with acute-on-chronic liver failure. PMID: 27981303
23. EPO levels were also found correlated positively with heme, TNF-alpha, IL-10, IP-10 and MCP-1 during cerebral malaria. PMID: 27441662
24. Three single nucleotide polymorphisms are associated with increased risk of diabetic retinopathy in a Chinese Han population. PMID: 27190272
25. Pharmacokinetic animal studies revealed strongly 15.6-fold plasma half-life extension for the PASylated EPO (83.16 +/- 13.28 h) in comparison to epoetin alpha (8.5 +/- 2.4 h) and darbepoetin alpha (25.3 +/- 2.2h). PMID: 28168382
26. Secreted MIR122 reached the kidney and reduced expression of erythropoietin, contributing to inflammation-induced anemia. PMID: 27477940
27. this paper shows that Epo could directly down-regulate pro-inflammatory T cell responses without affecting T cell activation status PMID: 27208431
28. findings suggest that erythropoietin levels in anemia of unknown etiology, although elevated, remain inappropriately low, particularly when compared with other forms of anemia. This suggests a relative erythropoietin deficiency or a blunted erythroid cell response. PMID: 26747131
29. Plasma IGFBP-1 was significantly associated with plasma EPO concentration in acute kidney injury, suggesting an unknown mechanism related to systemic stress conditions for EPO regulation in AKI. PMID: 26479890
30. Our results suggest that EPO/EPOR pathway promotes gastric cancer formation, proliferation, migration, and decreases apoptosis PMID: 27086036
31. These results suggest that both EpoR-positive and EpoR-negative cancer cells could be regulated by exogenous Epo. However, an increased response to erythropoietin was observed in the EpoR-positive cells. Thus, erythropoietin increases the risk of tumor progression in colon cancer and should not be used to treat anemia in this type of cancer. PMID: 27543111
32. Overexpression of EPO is associated with clear cell renal cell carcinoma. PMID: 27468719
33. EPO may play an important role in stem cell mobilization through up regulating HGF in mesenchymal stem cells and inducing migration of hematopoietic stem/progenitor cells PMID: 27865586
34. A review of contemporary aspects of EPO relating to chronic liver disease. [review] PMID: 26919118
35. Hepatic EPO synthesis is not enhanced in cirrhosis. PMID: 26924722
36. Conclusion: Anemia in cancers was not because of inadequate Epo or Fe levels, but because of improper Epo response. PMID: 26838000
37. In multivariate survival analysis, age, Epo and EpoR were independent prognostic factors related to overall survival in hepatocellular carcinoma. PMID: 26097591
38. Suggest that hypoxia prevents EPO suppression, and exaggerates the plasma volume reduction induced by bed rest. PMID: 27081163
39. Inadequate erythropoietin response may partly explain anemia in anorexia nervosa. PMID: 26049959
40. these findings suggest that TGF-beta suppression and EPO stimulation promote erythropoiesis of CD34(+)CD31(+) progenitor cells derived from hPSCs. PMID: 26012423
41. Our findings have important potential clinical implications, indicating that EPO supplementation in rhabdomyosarcoma patients may have the unwanted side effect of tumor progression. PMID: 26412593
42. suggest that rhEPO regulates apoptosis-related genes and affects apoptosis in the hippocampus of aging rats by upregulating SIRT. PMID: 26261574
43. Higher levels of endogenous erythropoietin are associated with incident heart failure in older adults. PMID: 26721912
44. Erythropoietin protects mouse renal tubular basement membrane by promoting bone marrow cells to generate and secrete miR-144, which, in turn, inhibits activation of the tPA/MMP9-mediated proteolytic network. PMID: 26469975
45. The review describes the induction of erythropoietin gene expression in liver, reproouctive and hemopoietic systems during hypoxia or a state of proliferation. PMID: 26995951
46. Our data suggest that rs507392 and rs551238 in the erythropoietin gene probably act to lessen the risk for diabetic retinopathy (DR) in a Chinese cohort with type 2 diabetes mellitus (T2DM). PMID: 25675872
47. Data suggest maternal circulating 25-hydroxyvitamin D during mid-pregnancy and at delivery is inversely related to serum EPO; an indirect relation observed between circulating vitamin D and circulating hemoglobin is at least partly mediated by EPO. PMID: 26447159
48. This review gleans these different strategies and highlights the leading molecular recognition elements that have potential roles in rHuEPO doping detection. PMID: 25058943
49. The addition of salt (even low concentrations of the strong chaotrope salt guanidinium hydrochloride) also exponentially decreased the initial rate of soluble erythropoietin non-native aggregation at 37 degrees C storage PMID: 25628168
50. In very preterm infants, whether elevated perinatal erythropoietin (EPO) concentrations are associated with increased risks of indicators of brain damage, was determined. PMID: 25793991
顯示更多

收起更多
相關(guān)疾病：

Microvascular complications of diabetes 2 (MVCD2)
亞細(xì)胞定位：

Secreted.
蛋白家族：

EPO/TPO family
組織特異性：

Produced by kidney or liver of adult mammals and by liver of fetal or neonatal mammals.
數(shù)據(jù)庫鏈接：

HGNC: 3415

OMIM: 133170

KEGG: hsa:2056

STRING: 9606.ENSP00000252723

UniGene: Hs.2303

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
VIM Recombinant Monoclonal Antibody

Applications: ELISA, IHC, IF

Species Reactivity: Human